BCM
EPZM

BlueCrest Capital Management’s Epizyme, Inc EPZM Stock Holding History

BlueCrest Capital Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-17,813
Closed -$339K – 1168
2017
Q3 		$339K Buy
+17,813
New +$272K 0.01% 605

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

BlueCrest Capital Management's EPZM Position: Q4 2017 in Review

BlueCrest Capital Management sold out of Epizyme, Inc (EPZM) in Q4 2017, closing a stake of 17,813 shares — an estimated $339K sold.

BlueCrest Capital Management first reported a position in EPZM in Q3 2017 and held it in 1 quarter. The position peaked at $339K in Q3 2017. 101 funds tracked by Wall St. Rank hold EPZM as of Q4 2017.

  • BlueCrest Capital Management reported no remaining Epizyme, Inc position as of Q4 2017 after selling out during the quarter.
  • BlueCrest Capital Management sold 17,813 Epizyme, Inc shares in Q4 2017, an estimated $339K.
  • BlueCrest Capital Management first reported a position in Epizyme, Inc in Q3 2017 and held it in 1 quarter.
  • BlueCrest Capital Management's Epizyme, Inc position peaked at $339K in Q3 2017.
  • 101 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2017.

Based on BlueCrest Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.